CUMULATIVE INDEX 1999

Volume 20

March	FLEXIBLE BRONCHOSCOPY IN THE 21ST CENTURY, pages 1–222
June	INTENSIVE CARE UNIT COMPLICATIONS, pages 223–473
September	PNEUMONIA, pages 475–696
December	IMAGING, pages 697–875

Note: Page numbers of article titles are in **boldface** type.

Abdominal compartment syndrome, in ICU, 334–335
Abdominal distention, in ICU, 340
Abdominal imaging, in diagnosis of gastrointestinal complications in ICU, 331–332
Abscesses, lung, 823–824
Acalculous cholecystitis, in ICU, 335–336
Acquired immunodeficiency syndrome (AIDS), bronchogenic carcinoma in, bronchoscopy in, 68
  bronchoscopy in, **63–76**. See also *Human immunodeficiency virus (HIV) infection, bronchoscopy in.*
    for infection control measures, 73
  tuberculosis and, radiology of, 560
Acute eosinophilic pneumonia, 637
Acute lung injury, ventilator-associated, 238–239
Acute mesenteric ischemia, in ICU, 332–334
Acute pancreatitis, in ICU, 336–337
Acute renal failure (ARF), in ICU, **347–366**. See also *Intensive care unit (ICU), acute renal failure in.*
Acute respiratory distress syndrome (ARDS), acute renal failure in ICU and, 361
Adenosine, complications of, 278–279
Adrenal insufficiency, 402–405
Adrenal metastasis, MR imaging for, 786–787
Afterload, left ventricular, positive intrathoracic pressure effects on, 225
Age, as factor in drug interactions in ICU, 395
AIDS. See *Acquired immunodeficiency syndrome (AIDS).*
Airway stents, **139–151**
  complications, 146–149
  flexible bronchoscopy for, 4
  metal stents, 141–144
  technical problems associated with, 145–146
  tube stents, 140–141
  types, 139–144
  wallstents, 144
Airways, colonization, implications for, 480–481
  complications, in lung transplantation, imaging of, 828–829
  conducting, 828–829
    implications for, 480
    treatment, implications for, 480
  imaging of, **761–773**
    asthma, 770–771
    bronchiectasis, 764–766
    bronchiolitis, 767–769
    haemoptysis, 761–763
    small airways disease, 767–771
  mechanical ventilation effects on, 239–243
  respiratory gas exchange, 478–479
  small, disease of, imaging of, 767–771
Allergic angiitis, and granulomatosis, 639–640
Alternative arterial sites, comparison of, 250–252
Alveolar hemorrhage syndromes, 640–641
Alveolar macrophage, pneumonia caused by, 565
Alveolitis, allergic, extrinsic, 632–634
  fibrosing, high-resolution CT in, **739–760**. See also *Computed tomography (CT), high-resolution, in fibrosing alveolitis.*
    pathologic aspects of, 742–743
    prognosis, evaluation, 752–754
    reversibility of, evaluation, 752–754
Aminoglycosides, for community-acquired pneumonia, 594
Anesthesia/anesthetics, for endobronchial laser therapy, complications associated with, 113
Aneurysms, aortic, MR imaging for, 779–780
Angiitis, allergic, and granulomatosis, 639–640
Angiography, in massive hemoptysis, 100–101
Antibiotics, for community-acquired pneumonia, **589–598**. See also *Community-acquired pneumonia, treatment, antibiotics in.*
  for infection of pleural space, 611–612
  for nosocomial pneumonia, 660–661
  for ventilator-associated pneumonia, 295–297, 685–688
Antigens, detection of, in community-acquired pneumonia, 535–536
Anti-glomerular basement membrane disease, 641–642
Anti-inflammatory therapy, for asthma, bronchoscopy in assessment of, 179–183
Antimicrobial agents, for atypical pathogen community-acquired pneumonia, 494
Antimicrobial resistance, in ICU, **303–315**. See also *Intensive care unit (ICU), antimicrobial resistance in.*
Aortic aneurysm, MR imaging for, 779–780
Aortic dissection, MR imaging for, 776–778
Aortic ulcer, penetrating, MR imaging for, 778–779
Aortitis, MR imaging for, 780
Arrhythmias, drug-related, in ICU, 269–278. See also *Intensive care unit (ICU), cardiac complications in, drug-related arrhythmias.*

Arrhythmias *(Continued)*
pulmonary artery catheterization and, 256–258
Arterial catheters, neurologic complications in, 429–430
Arterial pressure monitoring, complications of, 249–252
Arterial puncture, pulmonary artery catheterization and, 252–254
Aspiration, pneumonia caused by, 565
transthoracic needle, in community-acquired pneumonia, 538
transtracheal, in community-acquired pneumonia, 537–538
Aspiration pneumonia, radiology of, 551–552
Astemizole, arrhythmias caused by, 275
Asthma, anti-inflammatory therapy for, bronchoscopy in assessment of, 179–183
bronchoalveolar lavage in, 161–168
flexible bronchoscopy for, 10–11
imaging of, 770–771
induced sputum in, 161–168
provocation studies in, bronchoscopy for, 168–179
Asthma research, bronchoscopy in, **153–189**
biopsy, 160–161
bronchial brushings, 160–161
bronchoalveolar lavage, 160
specimen processing in, 160–161
technical issues related to, 154–160
Asystole, pulmonary artery catheterization and, 257
Atypical pneumonia syndrome, versus pneumonia syndrome, 489–490
Autofluorescence bronchoscopy, for lung cancer, 5–6

Bacteria, resistant, emergence and spread of, prevention, in ICU, 310–314
Bacterial pneumonia, following lung transplantation, 82–83
in HIV-infected persons, bronchoscopy in, 50
Beta-lactams, for community-acquired pneumonia, 593–594
Biotransformation, cytochrome system of, 389–390
Blastomycosis, 511–514
acute pulmonary, 511–512
chronic pulmonary, 512
clinical presentation, 511–512
disseminated, 512
epidemiology, 511
microbiology of, 511
pathogenesis, 511
treatment, 513–514
Bleeding, gastrointestinal, in ICU, 338–339
Blood cultures, in community-acquired pneumonia, 535
Brachytherapy, 133–136
as curative therapy, 135–136
complications, 136
contraindications, 134
dosage in, 134
endobronchial, efficiency of, 134–135
versus external beam radiation therapy, 135
with Nd:YAG laser, 135
for lung cancer, 6
history of, 133
indications, 134
patient selection for, 134
technique, 134
Bronchial brushings, in asthma research, 160–161
Bronchiectasis, bronchography in, 764–765
chest radiography in, 764
CT in, 765
high-resolution, 765–766
imaging of, 764–766
Bronchiolitis, cellular, imaging of, 770
obliterative, imaging of, 768
respiratory, imaging of, 769–770
Bronchiolitis obliterans, with intraluminal polyps, imaging of, 767–768
Bronchiolitis obliterans with organizing pneumonia (BOOP), 630–632
Bronchoalveolar lavage, flexible bronchoscopy for, 2–3
in asthma, 161–168
in asthma research, 160
in diagnosis of respiratory infectious complications in ICU, 293–294
in HIV-infected persons, 70
nonbronchoscopic, in HIV-infected persons, 72
Bronchogenic carcinoma, in AIDS patients, bronchoscopy in, 68
Bronchography, in bronchiectasis, 764–765
Bronchopleural fistulas, flexible bronchoscopy for, 11
in ICU, 320–321
Bronchoscopes, autofluorescence, for lung cancer, 5–6
flexible, described, 1–2
rigid, described, 2
Bronchoscopic ultrasonography, flexible bronchoscopy for, 3–4
Bronchoscopy, fiberoptic, in community-acquired pneumonia, 538–539
flexible. See *Flexible bronchoscopy.*
fluorescence, in lung cancer detection, 56–57
in AIDS, **63–76**
in HIV infection, **63–76**
in massive hemoptysis, **89–105**. See also *Massive hemoptysis, bronchoscopy in.*
of thorax, compared with transthoracic needle biopsy, 816–817
research, flexible bronchoscopy for, 12
virtual, **210–217, 725–730**. See also *Virtual bronchoscopy.*
Bronchoscopy suite, health care workers in, radiation safety for, **33–38**. See also under *Radiation.*
recommendations related to, 37–38
Bullae, infected, 823–824
Bundle branch blocks, pulmonary artery catheterization and, 257

Calcium channel blockers, complications of, 279
Calcium disorders, in ICU, 404–408
hypercalcemia, 406–408
hypocalcemia, 404–406
physiology of, 404
Cancer, chest wall, MR imaging of, 790
diaphragmatic, MR imaging of, 790
esophageal, flexible bronchoscopy for, 12
lung. See *Lung cancer.*
mediastinal, MR imaging of, 787–789
pleural, MR imaging of, 789–790
Candida albicans, nosocomial infection in ICU patients caused by, 309
Cardiac perforation, pulmonary artery catheterization and, 259
Cardiac system, complications affecting, in ICU, **269–285**. See also *Intensive care unit (ICU), cardiac complications in.*
Catheters, arterial, neurologic complications in, 429–430
epidural, neurologic complications in, 427
Ceftazidime, plus tobramycin, for ventilator-associated pneumonia in ICU, 296
Cell-mediated immunity, pneumonia caused by, 565
Central venous catheterization, neurologic complications in, 429

Chest physiotherapy, for nosocomial pneumonia, 660–663
Chest radiography, in bronchiectasis, 764–766
in lung volume reduction surgery, 855–856
Chest wall, cancer of, MR imaging for, 790
Chlamydia pneumoniae pneumonia, diagnostics tests in, 542–543
resolving rates, 629
Chlorhexidine, for nosocomial pneumonia, 661–662
Cholecystitis, acalculous, in ICU, 335–336
Chronic eosinophilic pneumonia, 635–637
Chronic obstructive pulmonary disease (COPD), pneumonia and, radiology of, 555
Churg-Strauss syndrome, 639–640
Chylothorax, in ICU, 324
Cisapride, arrhythmias caused by, 275
Clindamycin, for community-acquired pneumonia, 594
for ventilator-associated pneumonia in ICU, 295
CMV pneumonia. See *Cytomegalovirus (CMV) pneumonia.*
Coarctation, defined, 780
MR imaging for, 780–781
Coccidioidomycosis, 514–517
chronic pulmonary sequelae of, 515–516
clinical manifestations, 514–516
diagnosis, 516–517
disseminated, 516
epidemiology, 514
microbiology of, 514
pathogenesis, 514
treatment, 517
Coma, hyperosmolar, in ICU, 412
myxedema, in ICU, 410–411
Community-acquired pneumonia, admission decision for, prognostic scoring and outcome assessment tools in, **521–529**
assessment of criteria, 527–528
available, 522–524
design specifications for, 522
Fine's prediction rule, 524–526
Intermountain Health Care guideline for, 526–527
atypical pathogens in, **489–497**
antimicrobial agents for, 494
clinical and radiologic manifestations, 490–491
diagnosis, 492–493
future of, 493–494
mixed, 491–492
prevalence, 490
causes, 590
Chlamydia pneumoniae and, diagnostics tests in, 542–543
classification of, 600–601
diagnostic tests in, limitations, 590–591
diagnostics tests in, **531–548**
antigen detection in, 535–536
blood cultures, 535
fiberoptic bronchoscopy, 538–539
in nucleic acid detection, 536–537
invasive procedures, 537–539
noninvasive, 531–537
serologies, 536
sputum culture, 534–535
sputum Gram stain, 531–533
thoracentesis, 537
transthoracic needle aspiration, 538
transtracheal aspiration in, 537–538
drug-resistant pathogens in, **499–506**
gram-negative, 503–504
mechanisms of resistance in, 499–500
hospital admission for, criteria for, 599–600
hospitalized patients with, antibiotic alternatives for, 603–604
early discharge of, clinical stability in, 601–602
intravenous-to-oral antibiotic switch in, 602–603
strategies for, **599–605**
lung infections in, pathophysiology and treatment, 603
in the elderly, epidemiology, 563–564
prevention, 569–570
increased antimicrobial resistance in, 591–592
Mycoplasma pneumoniae and, diagnostics tests in, 541–542
pathogens in, 590
radiology of, 549–551
severe, **575–587**
causes, 577–578
clinical definition of, 575–576
comorbidity of, 576–577
diagnosis, 579–582
epidemiology, 576–578
ICU admission for, causes, 577
criteria for, 578–579
in the elderly, 579
incidence, 576
nonresponding patients with, evaluation, 581–582
outcome of, 582
prognostic factors in, 582–583
risk factors for, 578
treatment, 583–585
Streptococcus pneumoniae and, 592–593
treatment, aminoglycosides, 594
antibiotics, **589–598**
beta-lactams, 593–594
clindamycin, 594
fluoroquinolones, 594–595
macrolides, 594
quinolones, 595
tetracycline, 594
vancomycin, 594
Compartment syndromes in the extremities, 334
Computed tomography (CT), chest, and bronchoscopy, complementary relationships between, 201–202
contrast enhancement in, 703–705
for lung volume reduction surgery, 854–855
high-resolution, functional and pathophysiologic insights derived from, 754–757
in bronchiectasis, 765–766
in fibrosing alveolitis, **739–760**
diagnostic criteria, 750–752
features, 743–750
technical considerations in, 739–742
versus flexible bronchoscopy, 13
in bronchiectasis, 765
in emphysema, 847–854
in lung cancer, 698–705
in transthoracic needle biopsy, 809
in virtual bronchoscopy, 723–727
morphology of, 698–702
prior to and following lung volume reduction surgery, 854
spiral, in deep venous thrombosis, 374
in pulmonary embolism, **733–738**. See also *Pulmonary embolism, spiral CT in.*
versus flexible bronchoscopy, 12–13
Computed tomography (CT) densitometry, 702–703
Congestive heart failure, acute renal failure in ICU and, 361
Contrast venography, in deep venous thrombosis, 370–371
COPD. See *Chronic obstructive pulmonary disease (COPD).*
Corticosteroids, muscle impairment caused by, 446–447
Cryotherapy, 123–129

Cryotherapy *(Continued)*
complications, 128
equipment for, 125–127
for lung cancer, 6–7
history of, 123–124
indications, 125
patient selection for, 125
results, 127–128
technique, 125–127
theoretical and scientific basis of, 124–125
Cryptogenic fibrosing alveolitis, 739
CT. See *Computed tomography (CT).*
Cystic fibrosis, flexible bronchoscopy for, 12
Cytochrome system of biotransformation, 389–390
Cytomegalovirus (CMV) pneumonia, following lung transplantation, 83
radiology of, 558–560

D-dimer levels, in deep venous thrombosis, 372–373
Defibrillation, direct current cardioversion and, 280–281
Diabetic ketoacidosis, in ICU, 412
Dialysis disequilibrium syndrome, 429
Dialytic therapy, defining of, 349–351
Diaphragm, cancer of, MR imaging of, 790
Diaphragmatic paralysis, following lung transplantation, 841
Diarrhea, in ICU, 337–338
Direct current cardioversion (DC), and defibrillation, complications of, 280–281
Drugs, administration of, flexible bronchoscopy for, 11–12
arrhythmias caused by, ICU-related, 269–273
encephalopathies caused by, ICU-related, 426
in massive hemoptysis, 100
interactions, defined, 385
in ICU, **385–399**. See also *Intensive care unit (ICU), drug interactions in.*
muscle impairment caused by, 446–449
object, defined, 385
pneumonia caused by, 634–635
precipitant, defined, 385
pulmonary disease caused by, flexible bronchoscopy for, 12

Echocardiography, in deep venous thrombosis, 374–375
Edema, reperfusion, imaging of, 829–831
Effusions, parapneumonic, 816–823
Elderly, pneumonia in, **563–573**. See also *Pneumonia, in the elderly.*
Electrocautery, 129–133
complications, 133
equipment for, 130–132
history of, 129
indications, 130
patient selection for, 130
results, 132–133
technique, 130–132
theoretical and scientific basis of, 129–130
Electrolytes, abnormalities of, arrhythmias caused by, in ICU, 269–273
Electromyography (EMG), in ICU, 437–438
Electrosurgery, for lung cancer, 6–7
Embolism, pulmonary, hemodynamic monitoring and, 262–263
in deep venous thrombosis, 373
MR imaging of, 784–785
venous air, pulmonary artery catheterization and, 254–255
Embolization, in massive hemoptysis, 88–89
EMG. See *Electromyography (EMG).*
Emphysema, CT of, 847–854
pathophysiology, 845–846
radiologic evaluation, for lung volume reduction surgery, **845–861**
types, 845–846
Empyema, 816–823
in ICU, 324–325
Encephalopathy, ICU-related, 423–427
ischemic-anoxic, ICU-related, 425–426
metabolic, ICU-related, 424–425
Endobronchial biopsy, in HIV-infected persons, 56
Endobronchial brachytherapy, efficiency of, 134–135
versus external beam radiation therapy, 135
with Nd:YAG laser, 135
Endobronchial brushings, in HIV-infected persons, 56
Endobronchial laser therapy, **107–122**
anesthetic complications, 111
complications, 110–112
contraindications, 109
definitions associated with, 107–108
endobronchial complications, 111–112
equipment for, 108–109
historical perspective, 107
indications, 112
outcome following, 112–120
peri-operative complications, 112
personnel for, 108–109
physics of, 107–108
training for, 108–109
Endotracheal intubation, complications of, 239–240
neurologic complications in, 428
Enteral nutrition, complications of, 339–340
Enterobacteriaceae sp., community-acquired pneumonia caused by, 503–504
Enzymes, fibrinolytic, for infection of pleural space, 616
Eosinophilic pneumonia, acute, 637
Epidural catheters, neurologic complications in, 427
Erythromycin, arrhythmias caused by, 276
Esophageal cancer, flexible bronchoscopy for, 12
Euthyroid sick syndrome, in ICU, 411–412
Excoriations, 462
External beam radiation therapy, versus endobronchial brachytherapy, 135
Extrinsic allergic alveolitis, 632–634

Fever, Q, diagnostics tests in, 543
Fiberoptic bronchoscopy, in community-acquired pneumonia, 538–539
Fibrinolytic enzymes, for infection of pleural space, 616
Fibrinolytic therapy, for infection of pleural space, 616
Fibrosing alveolitis, high-resolution CT in, **739–760**. See also *Alveolitis, fibrosing; Computed tomography (CT), high-resolution, in fibrosing alveolitis.*
Fine's prediction rule, 524–526
Fistulas, bronchopleural, flexible bronchoscopy for, 11
in ICU, 320–321
tracheal arterial, massive hemoptysis caused by, 90–91
Flexible bronchoscope, described, 1–2
Flexible bronchoscopy, alternatives to, 12–14
chest CT and, complementary relationships between, 201–202
complications, 14
cost factors associated with, 14
for airway stents, 4

for asthma, 10–11
for bronchoalveolar lavage, 2–3
for bronchopleural fistulas, 11
for bronchoscopic ultrasonography, 3–4
for drug administration, 11–12
for esophageal cancer, 12
for interstitial lung disease, 11
for research, 12
for tracheobronchial stenosis, 11
future of, **1–17**
in asthma research, **153–189**. See also *Asthma research, bronchoscopy in.*
in cystic fibrosis, 12
in drug-induced pulmonary disease, 12
in gene therapy, 8–10
in ICU, 7–8
in lung cancer detection, **53–61**. See also *Lung cancer, early diagnosis of.*
in lung cancer research, **191–199**. See also *Lung cancer research, bronchoscopy in.*
in lung transplantation, 12, **77–87**
airway management, 77–78
bacterial pneumonia following, 82–83
CMV pneumonia following, 83
donor evaluation, 77
fungal infection following, 84
infections following, 82–84
mycobacterial pneumonia following, 84
Pneumocystis carinii pneumonia following, 84
rejection following, 78–82
acute rejection, diagnosis, 79–80
surveillance for, 80–81
chronic rejection, diagnosis, 81–82
classification of, 78–79
monitoring recipient following, 79
pathology associated with, 78–79
in massive hemoptysis, **89–105**. See also *Massive hemoptysis, bronchoscopy in.*
infection caused by, 14
infection control with, **19–32**
infection during, prevention, 24–29
transmission of, 19–24
airborne transmission, 20–22
cross-contamination, 19–20
distal spread, 22–24
extension within lung, 23
hematogenous dissemination, 23–24
upper to lower airways, 22–23
procedures used for, 2–4
risk factors associated with, 14
versus rigid bronchoscopy, in massive hemoptysis, 98
Fluorescence bronchoscopy, in lung cancer detection, 56–57
Fluoroquinolones, for community-acquired pneumonia, 594–595
Fluoroscopy, in transthoracic needle biopsy, 809
Friction, in ICU, 454
Fungal infection, following lung transplantation, 84
Fungal pneumonia, **507–519**. See also *Pneumonia, fungal.*
Fungus, in HIV-infected persons, bronchoscopy in detection of, 66

Gastrointestinal bleeding, in ICU, 338–339
Gastrointestinal system, complications of, in ICU, **329–345**. See also *Intensive care unit (ICU), gastrointestinal complications in.*
Gene therapy, flexible bronchoscopy for, 8–10
for lung cancer, 7
Glucose metabolism, disorders of, in ICU, 412–415
Gram stain, in community-acquired pneumonia, 531–533
Granulomatosis, allergic angiitis and, 639–640
Wegener's, 638–639

Haemophilus influenzae, community-acquired pneumonia caused by, 503
Haemoptysis, imaging of, 761–764
Haloperidol, arrhythmias caused by, 275–276
Health care workers, in bronchoscopy suite, radiation safety for, **33–38**. See also *Bronchoscopy suite, health care workers in, radiation safety for; Radiation.*
Heart, complications affecting, in ICU, **269–285**. See also *Intensive care unit (ICU), cardiac complications in.*
Heart rate, positive intrathoracic pressure effects on, 224
Hematomas, pulmonary, following transbronchial biopsy, 842
Hemodialysis, neurologic complications in, 429
Hemodynamic monitoring, complications of, **249–267**
pulmonary artery rupture, 259–264
Hemoptysis, massive. See *Massive hemoptysis.*
Hemorrhage, gastrointestinal, in ICU, 338–339
Hemothorax, defined, 322
in ICU, 322–324
Hepatic failure, acute renal failure in ICU and, 362
Histoplasmosis, 507–511
chronic upper lobe cavitary, 508–509
clinical presentations, 508–510
diagnosis, 510, 512–513
epidemiology, 507–508
microbiology of, 507
pathogenesis, 508
progressive disseminated, 509–510
treatment, 510–511
HIV infection. See *Human immunodeficiency virus (HIV) infection.*
Hospital-acquired pneumonia. See *Nosocomial pneumonia.*
Human immunodeficiency virus (HIV) infection, bacterial pneumonia in, bronchoscopy in, 64
bronchoalveolar lavage in, 70
bronchogenic carcinoma in, bronchoscopy in, 68
bronchoscopy in, **63–73**
endobronchial biopsy in, 70
endobronchial brushings in, 70
fungi in, bronchoscopy in, 66
interstitial pneumonitis in, bronchoscopy in, 68–70
Kaposi's sarcoma in, bronchoscopy in, 66–68
lymphomas in, bronchoscopy in, 68
nonbronchoscopic bronchoalveolar lavage in, 72
nontuberculous mycobacteria in, bronchoscopy in, 65–66
thoracoscopy in, 72
thoracotomy in, 72
transbronchial biopsy in, 70–72
transbronchial needle aspiration in, 70–72
transthoracic needle biopsy in, 72
tuberculosis in, bronchoscopy in, 65
viral pneumonia in, bronchoscopy in, 66
Humoral immunity, pneumonia caused by, 565
Hydration status, effects on radiographic appearance of pneumonia, 554–556
Hypercalcemia, in ICU, 406–408
Hyperkalemia, in ICU, 271–273
Hypernatremia, 417–418
diagnosis, 418
in ICU, 415–418

Hypernatremia *(Continued)*
management, 418
physiology of, 417–418
Hyperosmolar coma, in ICU, 412
Hypersensitivity pneumonia, 632–634
Hypertension, intra-abdominal, in ICU, 331, 334–335
pulmonary, MR imaging for, 782–784
Hypocalcemia, in ICU, 406–408
Hypoglycemia, in ICU, 415
Hypokalemia, in ICU, 269–270
Hypomagnesemia, in ICU, 270–271
Hyponatremia, causes, 416
euvolemic, 416
hypervolemic, 417
hypovolemic, 416
in ICU, 415–418
management, 417
physiology of, 415–416
Hypotension, acute renal failure in ICU and, 359–360
Hypothermia, acute renal failure in ICU and, 357–358
Hypothyroidism, in ICU, 410–411

Ibutilide, complications of, 279–280
ICU. See *Intensive care unit (ICU).*
Ileus, complications related to, in ICU, 340
Imaging, of lung transplantation, **827–844**. See also specific modality.
Imipenem, plus netilmycin, for ventilator-associated pneumonia in ICU, 296
Immobility, pressure ulcers due to, 456
Immune globulin, for nosocomial pneumonia, 662
Immune modulators, for respiratory gas exchange airways, 483–485
Immunocompromised hosts, opportunistic infections in, radiology of, 556–560
Impedance plethysmography, in deep venous thrombosis, 371
Infections, arterial cannulation and, 252
control, in bronchoscopy suite, **19–32**
diagnosis, transbronchial needle aspiration in, 46
flexible bronchoscopy and, 14
following lung transplantation, 82–84
imaging of, 835–839
hemodynamic monitoring and, 263–264
of pleural space, **607–622**. See also *Pleural space, infection of.*
skin, 462
Inflammatory response, pneumonia due to, 565–566
Influenza vaccines, in prevention of community-acquired pneumonia, in the elderly, 569–570
Intensive care unit (ICU), acute renal failure in, **347–366**
acute dialysis dosing in, 351–354
allergic reactions and, 355–356
anticoagulation in, 356–357
ARDS and, 361
central venous catheter hemodialysis access and, 358
circuit clotting in, 356–357
complications of, 355–360
congestive heart failure and, 361
dialysate solution/replacement fluid and, 360
dialytic therapy for, 349–351, 354–355
hepatic failure and, 362
hypotension and, 359–360
hypothermia and, 357–358
membrane biocompatibility in, 355–356
side effects, 355–360
substrate removal in, 358–359
systemic inflammatory response syndrome and, 360–361
admission to, by severe community-acquired pneumonia patients, causes, 577
criteria for, 578–579
adrenal function in, 401–404
antimicrobial resistance in, **303–315**
Candida and, 309
cross-transmission in, 303
factors affecting, 303–305
gram-negative pathogens in, 305–309
gram-positive pathogens in, 305
host defense in, 304
rates of, 305–309
resistant bacteria in, emergence and spread of, prevention, 310–314
antimicrobial use in, 304–305
evaluation, 309–310
calcium disorders in, 404–408
in ICU, 401–404
physiology of, 401
cardiac complications in, **269–285**
drug-related arrhythmias, astemizole, 275
cisapride, 275
complications of, 278–280
erythromycin, 276
haloperidol, 275–276
hemorrhagic events due to, management, 277–278
intracranial bleed due to, prognosis, 278
terfenadine, 275
thrombolytic therapy, 276
electrolyte abnormalities, 269–273
disorders of glucose metabolism in, 412–415
drug interactions in, **385–399**
absorption alterations, 386–388
age as factor in, 395
concomitant diseases and, 395
distribution alterations, 388
drug antagonism, 393
drug dosage, 394
enzyme induction, 390
enzyme inhibition, 390
excretion changes, 391–392
factors affecting, 393–395
metabolism alterations, 388–389
metabolites and, 394
minimization of, considerations in, 396–398
multiple drugs and, 395–396
narrow therapeutic index drugs, 396
risk factors for, 395–396
routes of administration, 394–395
synergism, 393
time course of, 393–394
EMG activity in, 437–438
endocrinologic complications of, **401–421**
flexible bronchoscopy for, 7–8
gastrointestinal complications in, **329–345**
abdominal compartment syndrome, 334–335
abdominal distention, 340
acalculous cholecystitis, 335–336
acute mesenteric ischemia, 332–334
acute pancreatitis, 336–337
clinical presentation, 329–330
diagnosis, 330–332
diarrhea, 337–338
enteral nutrition, 339–340
gastrointestinal bleeding, 338–339
intra-abdominal hypertension, 334–335
intra-abdominal sepsis, 335–336

parenteral nutrition, 339–340
metabolic complications of, **401–421**
muscle dysfunction in, **435–452**
assessment, 435–439
drug-related, 446–449
mechanical ventilation and, 441–442
myopathy-related, 448–449
respiratory muscle fatigue, 439
respiratory muscle impairment in sepsis, 439–441
vital capacity in, 435–436
neurologic complications in, **423–434**
arterial catheters and, 429–430
central venous catheterization and, 429
encephalopathies, 423–427
endotracheal intubation and, 428
epidural catheters and, 427
hemodialysis and, 429
intracranial pressure monitoring devices, 427
lumbar drains and, 427
lumbar puncture and, 427
mechanical ventilation and, 428–429
thrombolytic therapy and, 430–432
phrenic nerve stimulation in, 438–439
pleural complications in, **317–327**
bronchopleural fistula, 320–321
chylothorax, 324
empyema, 324–325
hemothorax, 322–324
pleural effusions, 317, 321–322
pneumothorax, 317–319
polyneuropathy of critical illness in, 443–446
respiratory infectious complications in, **287–301**
etiopathogenesis, 289–292
microbiological diagnosis, 292–295
bronchoscopic methods in, 292–294
nonbronchoscopic sampling, 294–295
nosocomial sinusitis, 297–299. See also *Nosocomial sinusitis, in ICU.*
prevention, 289–292
ventilator-associated, 288–289, 292
respiratory muscle pressures in, 436–437
severity scoring in, 348–362
skin complications in, **453–467**
friction, 454
moisture, 454–455
pathophysiology, 453–455
prevention, 459–460
risk assessment tools for, 458
shearing, 454
topical wound management, 460–462
thyroid function in, 408–412
transdiaphragmatic pressure in, 437
venous thromboembolism in, **367–384**. See also *Venous thromboembolism, in ICU.*
Intermountain Health Care guideline, 526–527
Interstitial lung disease, flexible bronchoscopy for, 11
Interstitial pneumonitis, in HIV-infected persons, bronchoscopy in, 68–70
Intra-abdominal hypertension (IAH), in ICU, 331, 334–335
Intra-abdominal sepsis, in ICU, 335–336
Intra-aortic balloon pump (IABP), complications of, 280
Intracranial pressure monitoring devices, neurologic complications in, 427
Ischemia, acute mesenteric, in ICU, 332–334

Kaposi's sarcoma, in HIV-infected persons, bronchoscopy in, 66–68
Ketoacidosis, diabetic, in ICU, 412
Knotting, pulmonary artery catheterization and, 258

Lasers, Nd:YAG, endobronchial brachytherapy with, 135
in massive hemoptysis, 100
Left ventricular afterload, positive intrathoracic pressure effects on, 225
Left ventricular filling, positive intrathoracic pressure effects on, 225
Legionella sp., pneumonia due to, resolving rates, 627
Legionellosis, diagnostics tests in, 539–541
Lesions, valvular, hemodynamic monitoring and, 263
Liver failure, acute renal failure in ICU and, 362
Lumbar drain, neurologic complications in, 427
Lumbar puncture, neurologic complications in, 427
Lung, abscess of, 826–827
functional impairment of, pneumonia caused by, 565
infections of, community-acquired pneumonia–related, pathophysiology and treatment, 603
mechanics of, physiology of, in ICU, 317
pneumothorax effects on, in ICU, 317–318
MR imaging of, 790–796
physiology of, 10
ventilator-associated injury of, 238–239
Lung cancer, **697–713**
autofluorescence bronchoscopy in, 5–6
brachytherapy for, 6
CT in, 698–705
early diagnosis of, **53–61**
bronchoscopic localization, 56
fluorescence bronchoscopy in, 56–57
rationale for, 57–58
sputum cytology examination in, 54
using sputum cells, 55–56
flexible bronchoscopy in, 4–7
cryotherapy and, 6–7
electrosurgery and, 6–7
photodynamic methods, 4–5
gene therapy for, 7
genetics of, flexible bronchoscopy in, 6
immunologic response to, 193–196
in therapeutic response and prognostic potential, 721
incidental, radiologic evaluation, 856–857
MR imaging in, 705, 785–787
non–small cell, staging of, 717–721
peripheral, early diagnosis of, 57
population at risk for, identification of, 54
prevalence, 55
recurrent, evaluation, 721
research in, bronchoscopy in, **191–199**
in diagnosis, 191–193
in therapy, 193
solitary pulmonary nodules in, 697–705
staging of, 706–711
transthoracic needle biopsy in, 705–706
Lung transplantation, acute rejection following, imaging of, 831–833
airway complications caused by, 828–829
chronic allograft rejection following, imaging of, 833–835
diaphragmatic paralysis following, imaging of, 841
flexible bronchoscopy in, 12, **77–87**. See also *Flexible bronchoscopy, in lung transplantation.*
imaging of, **827–844**
infection following, imaging of, 835–839
recurrence of primary disease following, imaging of, 841
Lung volume reduction surgery, chest radiography in, 855–856

Lung volume reduction surgery *(Continued)*
CT in, 854–855
impact on imaging of emphysema, 846–847
patient selection for, 854–855
perfusion scintigraphy in, 857–858
radiologic evaluation of emphysema for, **845–861**
role of imaging in patient selection for, 847
ventilation for, 857–858
Lymphadenopathy, mediastinal, MR imaging for, 786
Lymphomas, in HIV-infected persons, bronchoscopy in, 68

Macrolides, for community-acquired pneumonia, 594
Macrophage, alveolar, pneumonia caused by, 565
Magnetic resonance (MR) imaging, in chest wall cancer, 790
in diaphragmatic cancer, 790
in lung cancer, 705, 785–787
in mediastinal cancer, 787–789
in pleural cancer, 789–790
of great vessels of thorax, 775–785. See also under *Magnetic resonance (MR) imaging, of thorax.*
of lung, 790–796
of thorax, **775–803**
clinical indications, 776–785
for aortic aneurysm, 779–780
for aortic dissection, 776–778
for aortitis, 780
for coarctation, 780–781
for mediastinal veins, 781
for penetrating aortic ulcer, 778–779
for pulmonary embolism, 784–785
for pulmonary vasculature, 782–784
great vessels, 775–785
pulmonary functional, 790–796
Massive hemoptysis, angiography in, 100–101
bronchoscopy in, **89–105**
endobronchial tamponade in, 99–100
iced saline lavage in, 98
laser photocoagulation in, 100
rigid versus flexible, 98
timing of, 97–98
topical agents in, 98
causes, 91, 93
defined, 89–90
diagnosis, 94
embolization in, 100–101
epidemiology, 92
management, 82–85, 94–97
natural history of, 92, 94
nonbronchogenic therapy in, 100–101
pharmacologic therapy in, 100
prognosis, 92, 94
pulmonary artery rupture and, management, 102
radiation therapy in, 101–102
sources of, 90–91
surgical versus medical therapy for, 101–102
tracheal arterial fistula and, management, 102–103
Mechanical ventilation, airway complications of, 239–243
effect on respiratory muscles, 441–442
neurologic complications of, 428–429
pulmonary complications of, **223–247**
acute lung injury, 238–239
positive intrathoracic pressure, 223–228
pulmonary volutrauma, 228–239
Mediastinal lymphadenopathy, MR imaging for, 786
Mediastinal veins, MR imaging of, 781
Mediastinitis, fibrosing, 509
Mediastinum, cancer of, MR imaging of, 787–789
Metal stents, 141–144
Metronidazole, for ventilator-associated pneumonia in ICU, 295
Microscopic polyangiitis, 640
Misplacement, pulmonary artery catheterization and, 258–259
Moisture, in ICU, 454–455
Moraxella catarrhalis, community-acquired pneumonia caused by, 503
MR imaging. See *Magnetic resonance (MR) imaging.*
Mucociliary transport, pneumonia caused by, 565
Mucus, clearance of, implications for, 481–483
Muscles, respiratory, in ICU. See also under *Intensive care unit (ICU), muscle dysfunction in.*
physiology of, 435
Mycobacteria, nontuberculous, in HIV-infected persons, bronchoscopy in, 65–66
Mycobacterial pneumonia, following lung transplantation, 84
Mycoplasma pneumoniae pneumonia, diagnostic tests in, 541–542
radiology of, 550–551
resolving rates, 627–629
Myocardial infarction, thrombolytic therapy for, bleeding caused by, 276–277
Myopathy, acute, in ICU, 448–449
Myxedema coma, in ICU, 410–411

National Pressure Ulcer Advisory Panel (NPUAP) staging system, 457
Nd:YAG laser, endobronchial brachytherapy with, 135
in massive hemoptysis, 100
Neurologic system, complications of, 255
ICU-related, **423–434**. See also *Intensive care unit (ICU), neurologic complications in.*
Neuromuscular blocking agents, muscle impairment due to, 447–448
Non–small cell lung cancer, staging of, 717–721
Nosocomial pneumonia, **653–670**
antibiotic resistance in, 655–656
economic considerations with, 653–654
in the elderly, epidemiology, 564
prevention, 570
mortality rates, 653
neutropenia due to, treatment, 662
pathogenesis, 654–655
radiology of, 552–553
risk factors for, 655
stress ulcers in, treatment, 660
treatment, antibiotic issues in, 296–297
antibiotics in, 660–661
avoidance of large gastric volumes in, 658
biofilm prevention technology in, 659
biologic response modulators, 663
chest physiotherapy in, 660
chlorhexidine in, 661–662
continuous subglottic suctioning in, 659
drugs, 660–663
hand washing in, 656
humidification with heat and moisture exchangers in, 659
immune globulin, 662
nonpharmacologic, 656–660
oral intubation in, 658
postural oscillation/rotation in, 659–660
protective gowns and gloves in, 656–657

quality improvement team in, 660
routine maintenance of ventilator circuits in, 658
semi-erect positioning in, 658
suction catheter replacement in, 659
vaccines in, 662–663
Nosocomial sinusitis, in ICU, 297–299
clinical findings in, 298–299
diagnosis, 299
etiopathogenesis, 298
microbiology of, 299
treatment, 299
Nucleic acids, detection of, in community-acquired pneumonia, 536–537
Nutrition, enteral, complications of, 339–340
parenteral, complications of, 339–340
Nutritional status, pressure ulcers and, 456

Object drug, defined, 385
Obliterative bronchiolitis, imaging of, 768
Occupational radiation exposure, 35
Opportunistic infections, fungal, radiology of, 557–558
in immunocompromised patients, radiology of, 556–560
Oropharynx, colonization of, pneumonia caused by, 565

Pacemakers, temporary, complications of, 281–282
Panbronchiolitis, imaging of, 768–769
Pancreatitis, acute, in ICU, 336–337
Parapneumonic effusion, 817–820
Parenteral nutrition, complications of, 339–340
Penetrating atherosclerotic ulcer, MR imaging for, 778–779
Percutaneous drainage, of thorax, 817–824
Perfusion scintigraphy, in lung volume reduction surgery, 857–858
Pericardiocentesis, complications of, 282–283
Peripheral arterial cannulation sites, comparison of, 250
Pharmacokinetic interactions, defined, 385
Photocoagulation, laser, in massive hemoptysis, 100
Phrenic nerve stimulation, in ICU, 438–439
Physiotherapy, chest, for nosocomial pneumonia, 660–663
Plan-do-study-act (PDSA) cycles, continuous nature of, 663
Plethysmography, impedance, in deep venous thrombosis, 371
Pleura, cancer of, MR imaging for, 789–790
ICU-related, complications of, **317–327**. See also *Intensive care unit (ICU), pleural complications in.*
Pleural effusions, in ICU, 321–322
lung mechanics effects on, in ICU, 317
malignant, drainage and sclerosis of, 824
Pleural space, infection of, **607–622**
bacterial pathogens in, 608–609
causes, 607
clinical manifestations, 609
diagnosis, 609–611
epidemiology, 607
pathophysiology, 608
treatment, antibiotics, 611–612
drainage in, 612–617
analysis in, 613–614
clinical factors associated with, 612
imaging studies in, 612–613
microbiologic considerations in, 612
techniques, 616–617
thoracentesis, 614–616
fibrinolytic enzymes in, 616
Pneumococcal pneumonia, radiology of, 549–550
Pneumococcal vaccines, in prevention of community-acquired pneumonia, in the elderly, 569
Pneumocystis carinii pneumonia, following lung transplantation, 84
in HIV-infected persons, bronchoscopy in, 64–65
radiology of, 557
Pneumonia, acute eosinophilic, 637
alveolar macrophage and, 565
aspiration, radiology of, 551–552
aspiration and, 565
atypical manifestations, 554–556
bacterial, following lung transplantation, 82–83
in HIV-infected persons, bronchoscopy in, 64
bronchiolitis obliterans with organizing, 630–632
cell-mediated immunity and, 565
chronic eosinophilic, 635–637
CMV, radiology of, 558–560
community-acquired. See *Community-acquired pneumonia.*
COPD and, radiology of, 555
drug-induced, 634–635
eosinophilic, acute, 637
chronic, 635–637
epidemiology, 563–564
factors predisposing to, 564–566
fungal, **507–519**
blastomycosis, 511–514
coccidioidomycosis, 514–517
histoplasmosis, 507–511
hospital-acquired. See *Nosocomial pneumonia.*
humoral immunity and, 565
hypersensitivity, 632–634
in the elderly, **563–573**
causes, 566–567
clinical manifestations, 566
diagnosis, 567–568
epidemiology, 563–564
prevention, 569–571
severe, 579
treatment, 568–569
inflammatory response and, 565–566
long-term care facility-acquired, in the elderly, epidemiology, 564
lung function impairment and, 565
mortality associated with, 568
mucociliary transport and, 565
mycobacterial, following lung transplantation, 84
mycoplasma, radiology of, 550–551
noninfectious mimics of, evaluation, 630–643
nonresolving, **623–651**. See also *Pneumonia, slowly resolving.*
defined, 623
evaluation, 629–643
pulmonary neoplasms in, evaluation, 630
resolution rates according to pathogen, 626–629
nosocomial. See *Nosocomial pneumonia.*
treatment, antibiotic issues in, 296–297
oropharyngeal colonization and, 565
pneumococcal, radiology of, 549–550
Pneumocystis carinii, following lung transplantation, 84
in HIV-infected persons, bronchoscopy in, 64–65
radiology of, 557
postobstructive, delayed resolution of, 555–556
prognostic factors associated with, 568
radiology of, **549–562**
diagnostic effectiveness of, 549

Pneumonia *(Continued)*
hydration status and, 554–555
round, radiology of, 555
slowly resolving, **623–651**
defined, 623
host factors in, 624–626
tuberculous, radiology of, 551
ventilator-associated, diagnostic testing in, **671–679**
adverse effects, 675–676
bronchoscopic versus noninvasive sampling in, 675
culture findings in, interpretation of, 673–675
impact of outcome, 676–677
samples in, quality of, 673
in ICU, 292
antibiotics for, 295–297
microbiology of, 672–673, 684–685
prevention, 681–684
mechanical ventilator circuit in, 682
oropharyngeal and gastrointestinal decontamination in, 683
patient transport in, 683–684
ulcer, 683
vaccination in, 681–682
suspicion of, 671–672
treatment, **681–691**
antibiotic, 685–688
enteral feeding, 682–683
patient positioning in, 683
subglottic suctioning in, 683
viral, diagnostic tests in, 543
in HIV-infected persons, bronchoscopy in, 66
radiology of, 551
Pneumonia syndrome, versus atypical pneumonia syndrome, 489–490
Pneumonitis, interstitial, in HIV-infected persons, bronchoscopy in, 68–70
Pneumothorax, 820–823
lung mechanics effects on, in ICU, 317–319
pulmonary artery catheterization and, 254
Polyangiitis, microscopic, 640
Polyneuropathy of critical illness, 443–446
Positive end-expiratory pressure (PEEP), adverse effects of, 227–228
Positive intrathoracic pressure, physiologic effects of, mechanical ventilation and, 223–228
pulmonary hemodynamic effects of, 225–226
respiratory effects of, 226–227
systemic hemodynamic effects of, mechanical ventilation and, 223–225
Positron emission tomography (PET), in recurrent lung cancer evaluation, 725
in staging of non–small cell lung cancer, 717–721
of thorax, **715–724**
Postobstructive pneumonia, radiology of, 555–556
Post-transplant lymphoproliferative disorder, 839–840
Precipitant drug, defined, 385
Pressure ulcers, in ICU, **453–467**
equipment and, 456–457
immobility and, 456
nutritional status and, 456
pathophysiology, 453–455
pressure in, 453–454
prevention, 459–460
risk assessment tools for, 458
risk factors for, 454–457
tissue perfusion and, 456
topical wound management, 460–462
in spinal cord-injured patients, 462–464
staging of, 457–458
Protected specimen brush, in diagnosis of respiratory infectious complications in ICU, 293
Proteinosis, pulmonary alveolar, 642–643
Pseudoaneurysm, pulmonary artery, hemodynamic monitoring and, 261–262
Pseudomonas sp., community-acquired pneumonia caused by, 504
Pulmonary abnormalities, focal, evaluation, 715–717
Pulmonary alveolar proteinosis, 642–643
Pulmonary artery catheterization, complications of, 252–259
Pulmonary artery pseudoaneurysm, hemodynamic monitoring and, 261–262
Pulmonary artery rupture, hemodynamic monitoring and, 259–264
management, 261
mechanisms of, 259
presentation of, 261
risk factors for, 259–261
massive hemoptysis caused by, 102
Pulmonary blood flow, positive intrathoracic pressure effects on, 226
Pulmonary disease, drug-induced, flexible bronchoscopy for, 12
Pulmonary embolism, acute, spiral CT in, 733–736
chronic, 736–737
hemodynamic monitoring and, 262–263
in deep venous thrombosis, 373
MR imaging for, 784–785
spiral CT in, **731–738**
controversies associated with, 735
cost effectiveness of, 735
diagnostic algorithms associated with, 735–736
technology associated with, 733–735
Pulmonary hematomas, following transbronchial biopsy, 842
Pulmonary host defenses, **475–488**
treatment, implications for, 479–485
Pulmonary hypertension, MR imaging for, 782–784
Pulmonary nodules, solitary, 697–705
Pulmonary system, mechanical ventilation effects on, **223–247**. See also *Mechanical ventilation, pulmonary complications of.*
Pulmonary vascular resistance, positive intrathoracic pressure effects on, 225
Pulmonary vasculature, MR imaging of, 782–784
Pulmonary vasculitis, 638–642
Pulmonary venous capacitance, positive intrathoracic pressure effects on, 225–226
Pulmonary volutrauma, clinical and radiologic features, 236–238
management, 239
mechanical ventilation and, 228–239
clinical and radiologic features, 236–238

Q fever, diagnostic tests in, 543
Quinolones, for community-acquired pneumonia, 595

Radial artery, arterial pressure monitoring effects on, 249–251
Radiation, health effects of, 34–35
occupational exposure to, 35
protection from, 35–36
terminology associated with, 33–34
Radiation exposure, monitoring of, 36–37
occupational, 35

Radiation safety, for health care workers in bronchoscopy suite, **33–38**. See also *Bronchoscopy suite, health care workers in, radiation safety for; Radiation.*
Radiation therapy, external beam, versus endobronchial brachytherapy, 135
in massive hemoptysis, 101–102
Radiography, chest, in bronchiectasis, 764–766
in lung volume reduction surgery, 855–856
Radiology, of pneumonia, **549–562**. See also *Pneumonia, radiology of.*
Renal failure, acute, in ICU, **347–366**. See also *Intensive care unit (ICU), acute renal failure in.*
Reperfusion edema, imaging of, 829–831
Research bronchoscopy, flexible bronchoscopy for, 12
Respiratory defense mechanisms, 475–479
Respiratory gas exchange airways, 478–479
Respiratory muscle pressures, maximum, in ICU, 436–437
Respiratory muscles, impairment of, in sepsis, 439–441
in ICU, drugs impairing, 446–449
during weaning, 442–443
fatigue of, 439
mechanical ventilation effects on, 441–442
physiology of, 435
Respiratory system, infectious complications affecting, in ICU, **287–301**. See also *Intensive care unit (ICU), respiratory infectious complications in.*
Right ventricular filling, positive intrathoracic pressure effects on, 224
Rigid bronchoscope, described, 2
Rigid bronchoscopy, versus flexible bronchoscopy, in massive hemoptysis, 98
Round pneumonia, radiology of, 555

Sarcoidosis, diagnosis, transbronchial needle aspiration in, 46
Scintigraphy, perfusion, in lung volume reduction surgery, 857–858
ventilation-perfusion, in deep venous thrombosis, 373–374
Seizures, encephalopathies caused by, ICU-related, 426–427
Sepsis, intra-abdominal, in ICU, 335–336
respiratory muscle impairment in, 439–441
Serologic tests, in community-acquired pneumonia, 536
Serum lactate, in diagnosis of gastrointestinal complications in ICU, 330–331
Shearing, in ICU, 454
Sinuses, treatment, implications for, 480
Sinusitis, nosocomial, in ICU, 297–299. See also *Nosocomial sinusitis, in ICU.*
Skin, complications of, in ICU, **453–467**. See also *Intensive care unit (ICU), skin complications in.*
Skin care, special considerations in, 462–464
Skin tears, 462
Small airways disease, imaging of, 767–771
Spinal cord injuries, pressure ulcers in patients with, 462–464
Spiral CT, in deep venous thrombosis, 374
in pulmonary embolism, **731–738**. See also *Pulmonary embolism, spiral CT in.*
Sputum, induced, in asthma, 161–168
Sputum cells, lung cancer detection using, 55–56
Sputum culture, in community-acquired pneumonia, 534–535
Sputum Gram stain, in community-acquired pneumonia, 531–533
Staphylococcus aureus, community-acquired pneumonia caused by, 502
Stents, airway, **139–151**. See also *Airway stents.*
Streptococcus pneumoniae pneumonia, community-acquired, 500–502, 592–593
beta-lactam resistance in, 500–501
resolving rates, 626–627
Stress ulcers, in nosocomial pneumonia, treatment, 660
Sulcus tumors, superior, MR imaging of, 786
Superior sulcus tumors, MR imaging of, 786
Systemic inflammatory response syndrome, acute renal failure in ICU and, 360–361
Systemic venous return, positive intrathoracic pressure effects on, 224

Tachycardia, ventricular, pulmonary artery catheterization and, 257
Terfenadine, arrhythmias caused by, 275
Tetracycline, for community-acquired pneumonia, 594
Thoracentesis, for infection of pleural space, 614–616
in community-acquired pneumonia, 537
Thoracic duct injury, pulmonary artery catheterization and, 255
Thoracoscopy, compared with transthoracic needle biopsy, 816–817
in HIV-infected persons, 72
Thoracotomy, compared with transthoracic needle biopsy, 816–817
in HIV-infected persons, 72
Thorax, interventional techniques in, **705–826**. See also specific technique, e.g., *Transthoracic needle biopsy.*
MR imaging of, **775–803**. See also *Magnetic resonance imaging (MRI), of thorax.*
PET in, **715–724**
Thromboembolism, venous, in ICU, **367–372**. See also *Venous thromboembolism, in ICU.*
Thrombolysis, potential exclusions from, 277
Thrombolytic therapy, complications of, 276
neurologic complications in, 430–432
Thrombosis, hemodynamic monitoring and, 262–263
Thyroid function, in ICU, 408–412
physiology of, 408
Thyroid storm, in ICU, 409–411
Thyrotoxicosis, in ICU, 409–411
Tissue perfusion, pressure ulcers caused by, 456
Trachea, ultrasound imaging of, versus flexible bronchoscopy, 13
Tracheal arterial fistula, massive hemoptysis caused by, management, 102–103
Tracheobronchial stenosis, flexible bronchoscopy for, 11
Tracheostomy, complications of, 241–243
Transbronchial biopsy, in HIV-infected persons, 70
pulmonary hematomas following, 842
Transbronchial needle aspiration, **39–51**
complications associated with, 47
cough method in, 40–41
endobronchial lesions detected by, 46
hub-against-the-wall-method in, 40
in HIV-infected persons, 70, 72
indications, 39–40
infections detected by, 46
instrumentation, 40
jabbing method in, 40
peribronchial and submucosal disease detected by, 44–45
peripheral nodules or masses detected by, 45–46
piggy back method in, 40
results, 42–44

Transbronchial needle aspiration *(Continued)*
sarcoidosis detected by, 46
staging of carcinoma by, 42–44
technique, 40–42
Transdiaphragmatic pressure, in ICU, 437
Transesophageal echocardiography, complications of, 282
Transplantation, lung. See *Lung transplantation.*
Transthoracic needle aspiration, in community-acquired pneumonia, 538
Transthoracic needle biopsy, in HIV-infected persons, 70, 72
in lung cancer, 705–706
of thorax, 805–817
biopsy technique, 810–813
compared with bronchoscopy, thoracoscopy and thoracotomy, 816–817
complications, 813–815
contraindications, 805–806
cost analysis of, 816
efficacy of, 816
image guidance, 809–810
indications, 805–806
postbiopsy procedure, 813
prebiopsy procedure, 806–809
results, 816
Transtracheal aspiration, in community-acquired pneumonia, 537–538
Tube stents, 140–141
Tuberculosis, and AIDS, radiology of, 560
in HIV-infected persons, bronchoscopy in, 65
radiology of, 551
Tumors. See also *Cancer.*
superior sulcus, MR imaging of, 786

Ulcers, aortic, penetrating, MR imaging of, 778–779
pressure. See *Pressure ulcers.*
stress, in nosocomial pneumonia, treatment, 660
Ultrasonography, bronchoscopic, flexible bronchoscopy for, 3–4
in deep venous thrombosis, 371–372
in transthoracic needle biopsy, 809–810

Vaccines, for nosocomial pneumonia, 662–663
influenza, in prevention of community-acquired pneumonia, in the elderly, 569–570
pneumococcal, in prevention of community-acquired pneumonia, in the elderly, 569
Valvular lesions, hemodynamic monitoring and, 263
Vancomycin, 594
for ventilator-associated pneumonia in ICU, 295
Vasculitis, pulmonary, 638–642
Veins, mediastinal, MR imaging of, 781
Venography, contrast, in deep venous thrombosis, 370–371
Venous air embolism, pulmonary artery catheterization and, 254–255
Venous thromboembolism, in ICU, **367–384**
clinical features, 370
diagnosis, 370–375
epidemiology, 367
hypercoagulable states, 368–369
pathophysiology, 369–370
prevention, 375–378
risk factors for, 367–369
treatment, 378–380
venous catheters in, 369
Venous thrombosis, deep, diagnosis, 370–375
Ventilation, in lung volume reduction surgery, 857–858
mechanical. See *Mechanical ventilation.*
Ventilation-perfusion scintigraphy, in deep venous thrombosis, 373–374
Ventilators, lung injury associated with, management, 239
pneumonia caused by, diagnostic testing in, **671–679**. See also *Pneumonia, ventilator-associated, diagnostic testing in.*
in ICU, 292
antibiotics for, 295–297
respiratory infections in ICU caused by, 288–289
Ventricular tachycardia, pulmonary artery catheterization and, 257
Video-assisted thoracoscopic surgery (VATS), versus flexible bronchoscopy, 13–14
Viral pneumonia, diagnostic tests in, 543
radiology of, 551
Virtual bronchoscopy, **201–217**, **725–730**
advantages, 727–728
anecdotal observations of, 213
clinical challenges of, 214–215
CT images in, 725–726
educational and research applications, 213
future of, 214–215, 729–730
generating airway simulations by, 202–209
generating images by, 727
in lower airway diagnosis, 209–210
in staging, 210–212
in upper airway diagnosis, 209
interventional roles of, 212–213
limitations, 728–729
potential applications of, 209–213
technical features, 725–727
versus flexible bronchoscopy, 12–13
Volutrauma, pulmonary. See *Pulmonary volutrauma.*

Wallstents, 144
Weaning, respiratory muscles during, 442–443
Wegener's granulomatosis, 638–639